Advertisement
Singapore markets close in 6 hours 16 minutes
  • Straits Times Index

    3,292.84
    +5.09 (+0.15%)
     
  • Nikkei

    37,807.09
    +178.61 (+0.47%)
     
  • Hang Seng

    17,550.18
    +265.64 (+1.54%)
     
  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     
  • Bitcoin USD

    64,443.70
    +216.02 (+0.34%)
     
  • CMC Crypto 200

    1,392.59
    +10.02 (+0.72%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • Dow

    38,085.80
    -375.12 (-0.98%)
     
  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     
  • Gold

    2,346.60
    +4.10 (+0.18%)
     
  • Crude Oil

    83.84
    +0.27 (+0.32%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • FTSE Bursa Malaysia

    1,572.39
    +3.14 (+0.20%)
     
  • Jakarta Composite Index

    7,119.66
    -35.63 (-0.50%)
     
  • PSE Index

    6,556.62
    -18.26 (-0.28%)
     

What Analysts Recommend for Gilead Sciences in April 2018

What Analysts Recommend for Gilead Sciences in April 2018

In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.7 billion for fiscal 2017, which is a YoY decline of around 14%.